Tigermed Recognized with Frost & Sullivan 2021 China Clinical CRO Competitive Strategy Leadership Award
HANGZHOU, China, Nov. 29, 2021 /PRNewswire/ -- Tigermed, a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, announced that it has been awarded the Frost & Sullivan 2021 China Contract Research Organization (CRO) Competitive Strategy Leadership Award for its unwavering commitment to high standards, comprehensive service portfolio, and growing global impact. For more than half-century,...
Yidu Tech Maintains Rapid Growth Momentum in the First Half of FY2022
HONG KONG, Nov. 29, 2021 /PRNewswire/ -- Yidu Tech Inc. ("Yidu Tech" or the "Company, together with its subsidiaries and consolidated affiliated entities, the "Group", HKEx: 2158), a healthcare big data and artificial intelligence solutions provider, announced its unaudited consolidated interim results for the six months ended 30 September 2021 ("first half of FY2022" or the "Period"). During the Period,...
Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market
SHANGHAI and SAN DIEGO, Nov. 29, 2021 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze"), a clinical-stage pharmaceutical company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets, announced a $75 million Series A financing round. The financing was co-led by Vivo Capital and AdvanTech Capital with participation from RAYZ Investments, Nan Fung Life Sciences, Pivotal...
VISTA Eye Specialist Shares How It Thrives during the COVID-19 Pandemic
PETALING JAYA, Malaysia, Nov. 29, 2021 /PRNewswire/ -- As part of VISTA Eye Specialists' (VISTA) core value of 'Giving Back to the Community', VISTA does not only give for charity, but believes strongly in sharing of knowledge and experiences. Other than sharing via conferences and publications, VISTA actively accepts industry interns, organizes programs to mentor college students, and participates in...
Tang Prize Laureates Reflect on the Breakthroughs Made Possible by Cytokine Research
TAIPEI, Nov. 27, 2021 /PRNewswire/ -- Following the inspiring opening speech, "Future Perspective of Cancer Immunotherapy," delivered by Nobel Prize and Tang Prize laureate Prof. Tasuku Honjo at the 14th Asia Pacific Federation of Pharmacologist Conference (APFP) on November 26, the 2020 Tang Prize Laureate's Lecture for Biopharmaceutical Science, co-organized by the Tang Prize Foundation and The Pharmacological Society...
ASUS and Medical Professionals Showcase Five Smart Healthcare Achievements
SINGAPORE, Nov. 26, 2021 /PRNewswire/ -- ASUS Intelligent Cloud Services (AICS) today introduced five smart medical solutions during its AICS Medical Open House. The xHIS platform, the Lumos EMR search platform, the Drug Safety Service, the Miraico smart medical coding assistant and the Personal Healthcare App have the potential to make a transformative impact in the healthcare industry. ...
Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Starpharma showed that 100% of evaluable patients with Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease. DEP® cabazitaxel is a patented, detergent (polysorbate-80)-free, nanoparticle version of the conventional cancer drug, Jevtana® - a leading oncology agent used to treat advanced prostate cancer. Sales of Jevtana® exceeded...
Róbert Wessman-led Aztiq and Innobic join forces in $475m acquisition of Lotus Pharmaceutical and Adalvo to create a global pharmaceutical powerhouse
REYKJAVÍK, Iceland, Nov. 26, 2021 /PRNewswire/ -- Aztiq ("Aztiq"), a healthcare investor led by Alvogen Founder and Chairman Róbert Wessman, and Innobic (Asia) Company Limited ("Innobic"), a life sciences subsidiary of Thailand industrial group PTT, today announced the signing of a definitive agreement to acquire a 100% stake in Alvogen Emerging Market...
Starpharma releases positive DEP® phase 2 interim results in prostate cancer
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma today announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel. The company showed that 100% of evaluable patients with (Stage IV) metastatic prostate cancer have had efficacy responses, utilising one or more standard measures of disease. Prostate cancer is the 2nd...
Antengene Included in the MSCI Global Small Cap Indexes – MSCI China Index Constituent Stocks
SHANGHAI and HONG KONG, Nov. 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that according to the latest semi-annual review results of the world's leading index company MSCI,...
